



Revolution Medicines to Deliver Multiple Presentations at the 2025 American Association for Cancer Research (AACR) Annual Meeting

April 1, 2025

REDWOOD CITY, Calif., April 01, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced 11 oral and poster presentations will be featured at the American Association for Cancer Research (AACR) Annual Meeting in Chicago, held from April 25 – 30, 2025.

The first clinical data in non-small cell lung cancer from the Phase 1 study of zoldonrasib, a RAS(ON) G12D-selective inhibitor, will be featured in a late breaking oral presentation.

Details of the abstracts are listed below:

Revolution Medicines Oral Presentations:

Title: [Preliminary safety and antitumor activity of zoldonrasib \(RMC-9805\), an oral, RAS\(ON\) G12D-selective, tri-complex inhibitor in patients with KRAS G12D non-small cell lung cancer \(NSCLC\) from a Phase 1 study in advanced solid tumors](#)
Presenter: Kathryn Arbour, M.D., Memorial Sloan Kettering Cancer Center
Abstract Number: CT019
Session: New Frontiers in Precision Oncology
Date/Time: April 27; 5:00 p.m. – 5:15 p.m. CST

Title: [Discovery of RMC-5127, an oral, RAS\(ON\) G12V-selective, noncovalent, tri-complex inhibitor](#)
Presenter: Anne Edwards, Ph.D.
Abstract Number: ND06
Session: New Drugs on the Horizon: Part 2
Date/Time: April 27; 3:25 p.m. – 3:40 p.m. CST

Revolution Medicines Poster Presentations:

Title: [Early reduction in circulating tumor DNA \(ctDNA\) is associated with clinical activity of daraxonrasib \(RMC-6236\) in RAS mutant non-small cell lung cancer \(NSCLC\)](#)
Presenter: Jia Luo, M.D., Dana-Farber Cancer Institute
Abstract Number: LB218
Session: Late-Breaking Research: Clinical Research 1
Date/Time: April 28; 2:00 p.m. – 5:00 p.m. CST

Title: [Mechanisms of resistance to the RAS\(ON\) multi-selective inhibitor daraxonrasib \(RMC-6236\) in RAS mutant PDAC and potential resolution with RAS\(ON\) combination therapies](#)
Presenter: Mallika Singh, Ph.D.
Abstract Number: LB281
Session: Late-Breaking Research: Experimental and Molecular Therapeutics 3
Date/Time: April 29; 9:00 a.m. – 12:00 p.m. CST

Title: [Combination of RAS\(ON\) mutant-selective and multi-selective inhibitors sensitizes immune-refractory, RAS-driven preclinical models to immunotherapy](#)
Presenter: Mariela Moreno Ayala, Ph.D.
Abstract Number: 6046
Session: Adaptive Immunity in Tumors / Oncogenic Pathway-Mediated Regulation of Inflammation and Tumor Immunity
Date/Time: April 29; 2:00 p.m. – 5:00 p.m. CST

Collaborator Presentations

Title: [Distinct regulation of Cyclin D mediates heterogenous response to RAS inhibition in colorectal cancer models](#)
Presenter: Philip Choi, M.D., Ph.D., Memorial Sloan Kettering Cancer Center
Abstract Number: LB293
Session: Late-Breaking Research: Experimental and Molecular Therapeutics 3
Date/Time: April 29; 9:00 a.m. – 12:00 p.m. CST

Title: [Combining RAS\(ON\) G12C-selective and RAS\(ON\) multi-selective inhibitors overcomes sotorasib resistance driven by KRAS G12C amplification or NRAS G13R mutation](#)
Presenter: Hitendra Singh Solanki, Ph.D., Moffitt Cancer Center
Abstract Number: 5512
Session: Drug Resistance in Molecular Targeted Therapies 3
Date/Time: April 29; 2:00 p.m. – 5:00 p.m. CST

Title: [A RAS\(ON\) multi-selective inhibitor combination therapy triggers long-term tumor control through senescence-associated tumor-immune equilibrium in preclinical models of PDAC](#)
Presenter: Caroline Broderick, Ph.D., Memorial Sloan Kettering Cancer Center
Abstract Number: 5336
Session: CDK Inhibitors
Date/Time: April 29; 2:00 p.m. – 5:00 p.m. CST

Title: [Preclinical evaluation of RMC-7977, a multi-selective RAS\(ON\) inhibitor, as a therapeutic strategy for KRAS-mutant cholangiocarcinoma](#)
Presenter: Jingjing Jiang, Ph.D.
Abstract Number: 5691
Session: Oncogenes, Tumor Suppressor Genes, and Gene Products as Targets for Therapy 2
Date/Time: April 29; 2:00 p.m. – 5:00 p.m. CST

Title: [Mechanisms of resistance to RAS-GTP inhibition in pancreatic cancer](#)
Presenter: Joshua H. Choe, Dana-Farber Cancer Institute
Abstract Number: 5507
Session: Drug Resistance in Molecular Targeted Therapies 3
Date/Time: April 29; 2:00 p.m. – 5:00 p.m. CST

Title: [T-cell dependency of tumor regressions and complete responses with RAS\(ON\) multi-selective inhibition in preclinical models of PDAC](#)
Presenter: Margo I. Orlan, Penn Medicine
Abstract Number: 6405
Session: Checkpoints and Modulators of Tumor Microenvironment
Date/Time: April 29; 3:25 p.m. – 3:40 p.m. CST

About Revolution Medicines, Inc.

Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; and zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor, are currently in clinical development. The company anticipates that RMC-5127, a RAS(ON) G12V-selective inhibitor, will be its next RAS(ON) inhibitor to enter clinical development. Additional development opportunities in the company's pipeline focus on RAS(ON) mutant-selective inhibitors, including RMC-0708 (Q61H) and RMC-8839 (G13C). For more information, please visit www.revmed.com and follow us on [LinkedIn](#).

Revolution Medicines Media & Investor Contact:

media@revmed.com
investors@revmed.com